BACKGROUND AND AIMS: Psoriasis is a chronic inflammatory disorder associated with vascular inflammation, measured by 18-fluorodeoxyglucose positron emission tomography/computed tomography (18-FDG PET/CT), and an increased risk of myocardial infarction. Patients with psoriasis are also more likely to suffer from comorbid depression. Whether depression accelerates the development of subclinical atherosclerosis in psoriasis is unknown. METHODS: Patients were selected from within a larger psoriasis cohort. Those who reported a history of depression (N = 36) on survey were matched by age and gender to patients who reported no history of psychiatric illness (N = 36). Target-to-background ratio from FDG PET/CT was used to assess aortic vascular inflammation and coronary CT angiography scans were analyzed to determine coronary plaque burden. Multivariable linear regression was performed to understand the effect of self-reported depression on vascular inflammation and coronary plaque burden after adjustment for Framingham risk (standardized β reported). RESULTS: In unadjusted analyses, vascular inflammation and coronary plaque burden were significantly increased in patients with self-reported depression as compared to patients with psoriasis alone. After adjustment for Framingham Risk Score, vascular inflammation (β = 0.26, p = 0.02), total plaque burden (β = 0.17, p = 0.03), and non-calcified burden (β = 0.17, p = 0.03) were associated with self-reported depression. CONCLUSIONS: Self-reported depression in psoriasis is associated with increased vascular inflammation and coronary plaque burden. Depression may play an important role in promoting subclinical atherosclerosis beyond traditional cardiovascular risk factors. Published by Elsevier Ireland Ltd.
BACKGROUND AND AIMS: Psoriasis is a chronic inflammatory disorder associated with vascular inflammation, measured by 18-fluorodeoxyglucose positron emission tomography/computed tomography (18-FDG PET/CT), and an increased risk of myocardial infarction. Patients with psoriasis are also more likely to suffer from comorbid depression. Whether depression accelerates the development of subclinical atherosclerosis in psoriasis is unknown. METHODS:Patients were selected from within a larger psoriasis cohort. Those who reported a history of depression (N = 36) on survey were matched by age and gender to patients who reported no history of psychiatric illness (N = 36). Target-to-background ratio from FDG PET/CT was used to assess aortic vascular inflammation and coronary CT angiography scans were analyzed to determine coronary plaque burden. Multivariable linear regression was performed to understand the effect of self-reported depression on vascular inflammation and coronary plaque burden after adjustment for Framingham risk (standardized β reported). RESULTS: In unadjusted analyses, vascular inflammation and coronary plaque burden were significantly increased in patients with self-reported depression as compared to patients with psoriasis alone. After adjustment for Framingham Risk Score, vascular inflammation (β = 0.26, p = 0.02), total plaque burden (β = 0.17, p = 0.03), and non-calcified burden (β = 0.17, p = 0.03) were associated with self-reported depression. CONCLUSIONS: Self-reported depression in psoriasis is associated with increased vascular inflammation and coronary plaque burden. Depression may play an important role in promoting subclinical atherosclerosis beyond traditional cardiovascular risk factors. Published by Elsevier Ireland Ltd.
Authors: Alan C Kwan; Heidi T May; George Cater; Christopher T Sibley; Boaz D Rosen; João A C Lima; Karen Rodriguez; Donald L Lappe; Joseph B Muhlestein; Jeffrey L Anderson; David A Bluemke Journal: Radiology Date: 2014-04-22 Impact factor: 11.105
Authors: Carmela Alcántara; Paul Muntner; Donald Edmondson; Monika M Safford; Nicole Redmond; Lisandro D Colantonio; Karina W Davidson Journal: Circ Cardiovasc Qual Outcomes Date: 2015-03-10
Authors: Benjamin J W Chow; George A Wells; Li Chen; Yeung Yam; Paul Galiwango; Arun Abraham; Tej Sheth; Carole Dennie; Rob S Beanlands; Terrence D Ruddy Journal: J Am Coll Cardiol Date: 2010-03-09 Impact factor: 24.094
Authors: O Ahlehoff; G H Gislason; M Charlot; C H Jørgensen; J Lindhardsen; J B Olesen; S Z Abildstrøm; L Skov; C Torp-Pedersen; P R Hansen Journal: J Intern Med Date: 2010-11-29 Impact factor: 8.989
Authors: Nehal N Mehta; YiDing Yu; Rebecca Pinnelas; Parasuram Krishnamoorthy; Daniel B Shin; Andrea B Troxel; Joel M Gelfand Journal: Am J Med Date: 2011-08 Impact factor: 4.965
Authors: Peter Jensen; Ole Ahlehoff; Alexander Egeberg; Gunnar Gislason; Peter R Hansen; Lone Skov Journal: Acta Derm Venereol Date: 2016-01 Impact factor: 4.437
Authors: Taufiq Salahuddin; Balaji Natarajan; Martin P Playford; Aditya A Joshi; Heather Teague; Youssef Masmoudi; Mariana Selwaness; Marcus Y Chen; David A Bluemke; Nehal N Mehta Journal: Eur Heart J Date: 2015-07-18 Impact factor: 29.983
Authors: Bharati Kochar; Edward L Barnes; Millie D Long; Kelly C Cushing; Joseph Galanko; Christopher F Martin; Laura E Raffals; Robert S Sandler Journal: Am J Gastroenterol Date: 2017-11-14 Impact factor: 10.864
Authors: Billie K Alba; Jody L Greaney; Sara B Ferguson; Lacy M Alexander Journal: Am J Physiol Heart Circ Physiol Date: 2017-10-20 Impact factor: 4.733
Authors: Sundus S Lateef; Mina Al Najafi; Amit K Dey; Mariyam Batool; Khaled M Abdelrahman; Domingo E Uceda; Aarthi S Reddy; Maryia D Svirydava; Navya Nanda; Jenis E Ortiz; Nina Prakash; Justin A Rodante; Andrew Keel; Wunan Zhou; Marcus Y Chen; Martin P Playford; Heather L Teague; Ahmed A Tawakol; Joel M Gelfand; Tiffany M Powell-Wiley; Nehal N Mehta Journal: Atherosclerosis Date: 2020-07-29 Impact factor: 5.162
Authors: C Elise Kleyn; Peter S Talbot; Nehal N Mehta; Francesca Sampogna; Chris Bundy; Darren M Ashcroft; Alexa B Kimball; Peter C M van de Kerkhof; Christopher E M Griffiths; Fernando Valenzuela; Joelle M van der Walt; Tsion Aberra; Lluís Puig Journal: Acta Derm Venereol Date: 2020-01-07 Impact factor: 3.875